Tumor Response

The majority of patients with measurable disease experienced tumour shrinkage with BRAFTOVI + cetuximab vs control arm*

*Irinotecan based treatment regimen

Best percentage change in tumour response per primary analysis^3,a

Reprinted with permission from Massachusetts Medical Society.

• The sum of longest diameter change includes patients with measurable disease per RECIST v1.1 with a baseline and at least 1 post-baseline scan. Only patients with measurable disease are included in the above waterfall plots^3,8

^a The asterisks indicate patients who had a complete response, partial response, or stable disease with respect to target lesions but who had a new lesion, a progressing nontarget lesion, or both.³